You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盟科藥業(688373.SH):公司注射用MRX-4序貫口服康替唑胺片治療複雜性皮膚和軟組織感染的中國Ⅲ期臨牀試驗已順利舉辦研究者會議
格隆匯 09-21 15:41

格隆匯9月21日丨有投資者向盟科藥業(688373.SH)提問:注射用MRX-4什麼時候能夠完成臨牀?

盟科藥業回覆:2023年上半年,公司注射用MRX-4序貫口服康替唑胺片治療糖尿病足感染的全球Ⅲ期臨牀試驗中國首家臨牀研究中心啟動,同時公司在歐洲、拉丁美洲等國家提交的臨牀試驗申請新增獲得了5個國家的批准,准予在保加利亞、斯洛伐克、克羅地亞、波蘭和巴西開展臨牀試驗,美國的患者招募工作在同步進行中。截至2023年6月30日,該臨牀試驗已完成中國研究者會議的召開,中國共有16家研究中心參加本次研究。公司注射用MRX-4序貫口服康替唑胺片治療複雜性皮膚和軟組織感染的中國Ⅲ期臨牀試驗已順利舉辦研究者會議,計劃將有超過50家研究中心參加本次臨牀試驗,計劃入組不少於300例患者,近日已正式啟動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account